Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: Results of a 26-week trial

Rheumatology

Volumn 42, Issue 10, 2003, Pages 1207-1215

  Pavelka, K ^b   Recker, D P ^a   Verburg, K M ^a  

^a PFIZER INC   (United States)

^b INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

Author keywords

Diclofenac; Gastroduodenal ulcers; Rheumatoid arthritis; Valdecoxib

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; VALDECOXIB;

ABDOMINAL PAIN; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM ULCER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; FEMALE; GASTRITIS; GASTRODUODENAL ULCER; GASTROINTESTINAL ENDOSCOPY; HEADACHE; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SLOW RELEASE FORMULATION; STOMACH EROSION; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOENZYMES; ISOXAZOLES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PAIN MEASUREMENT; PEPTIC ULCER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0141962671     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg359     Document Type: Article

References (40)

1. Borda IT, Koff R. NSAIDs: a profile of adverse effects. Philadelphia: Hanley and Belfus Inc., 1995.
2. Faucheron JL. Toxicity of non-steroidal anti-inflammatory drugs in the large bowel. Eur J Gastroenterol Hepatol 1999;11:389-92.
3. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
4. Masferrer JL, Zweifel BS, Manning PT et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
5. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 1991;324:1716-25.
6. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-14.
7. Sigthorsson G, Simpson RJ, Walley M et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal antiinflammatory drug enteropathy in mice. Gastroenterology 2002;122:1913-23.
8. Roth SH, Bennet SE, Caldron PH. Endoscopic evaluation of the long-term effects of diclofenac sodium and naproxen in elderly patients with arthritis. Clin Drug Invest 1995; 9:171-9.
9. Roth SH, Bennett R, Caldron P et al. A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. J Rheumatol 1994;21:1118-23.
10. Hawkey CJ. Management of gastroduodenal ulcers caused by non-steroidal anti-inflammatory drugs. Bailliere's Best Pract Res Clin Gastroenterol 2000;14:173-92.
11. Hayllar J, Macpherson A, Bjarnason I. Gastroprotection and nonsteroidal anti-inflammatory drugs (NSAIDs). Rationale and clinical implications. Drug Saf 1992;7: 86-105.
12. Lefkowith JL, Verburg KM, Geis GS. Clinical efficacy and safety of celecoxib. In: Vane JR, Botting RM, eds. Defining the role of COX-2 inhibitors in inflammatory and other diseases. London: William Harvey Press, 2001:461-81.
13. Morrison B, Simon TJ, DeTora L, Sperling R. Rofecoxib: clinical studies. In: Vane JR, Botting RM, eds. Defining the role of COX-2 inhibitors in inflammatory and other diseases. London: William Harvey Press, 2001:541-70.
14. Talley JJ, Brown DL, Carter JS et al. 4-[5-Methyl-3-phenylisoxazol-4-yl] benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000;43:775-7.
15. Daniels SE, Desjardins PJ, Talwalker S et al. The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J Am Dent Assoc 2002;133:611-21.
16. Camu F, Beecher T, Recker DP et al. Valdecoxib, a COX-2 specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 2002; 9:43-51.
17. Hochberg MC, Chang RW, Dwosh I et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
18. Fries JF. The assessment of disability: from first to future principles. Br J Rheumatol 1983;22(Suppl.):48-58.
19. ARA Glossary Committee. Dictionary of rheumatic disease, Vol. 1. Signs and symptoms. New York: Contact Associates International Ltd, 1988.
20. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
21. Steinbrocher O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;140:659-662.
22. Cooperating Clinics Committee of American Rheumatism Association. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965;8:302-34.
23. Ward JR, Williams HJ, Egger MJ et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1983;26:1303-15.
24. Lanza FL, Royer GL Jr, Nelson RS. Endoscopic evaluation of the effect of aspirin, buffered aspirin and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980;303:136-8.
25. Bellamy N, Anastassiades TP, Buchanan WW et al. Rheumatoid arthritis antirheumatic drug trials. III. Setting the delta for clinical trials of antirheumatic drugs - results of a consensus development (DELPHI) exercise. J Rheumatol 1991;18:1908-15.
26. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1998;75:800-2.
27. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
28. Henry D, Lim LL, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 1996;312: 1563-6.
29. Goldstein JL, Correa P, Zhao WW et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase inhibitor compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96: 1019-27.
30. Emery P, Zeidler H, Kvien TK et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 1999;354:2106-11.
31. Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. J Am Med Assoc 1999;282:1921-8.
32. Hawkey C, Laine L, Simon T et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43:370-7.
33. Laine L, Harper S, Simon T et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Study Group. Gastroenterology 1999;117:776-83.
34. Goldstein JL, Silverstein FE, Agrawal NM et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-90.
35. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis, the CLASS study: a randomized controlled trial. J Am Med Assoc 2000;284:1247-55.
36. Mamdani M, Rochon PA, Juurlink DN et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. Br Med J 2002;325:624-7.
37. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-8.
38. Kivitz A, Eisen G, Zhao W et al. The COX-2 specific inhibitor valdecoxib is as effective as naproxen in treating symptomatic osteoarthritis of the knee and demonstrates reduced gastrointestinal ulceration. J Fam Pract 2002;51: 530-7.
39. Sikes D, Agrawal N, Zhao WW et al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with OA. Eur J Gastroenterol Hepatol 2002;14:1101-11.
40. Bensen W, Weaver A, Espinoza L et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology 2002;41: 1008-16.